About


The Origin

Founded in 2013, Co-founder Dr. Nader Nourizad, A pioneer in pyrosequencing and reagentengineering, believed the market was in desperate need of high quality, high yield, and above all else, truly pure reagents.

Pharmozyme has since developed proprietary technology to produce the world’s purest reagents, introducing the world’s first Taq Polymerase free from bacterial and animal DNA contamination. In the coming years Pharmozyme plans to release a variety of contamination free reagents, supporting new technologies in sequencing and DNA research. Its future path will include the production of highly accurate and sensitive kits for medical diagnostics.

Pharmozyme Inc. manufactures and sells the world’s purest enzymes that are free from bacterial and animal DNA contamination, used for supporting new technologies in DNA Amplification, Sequencing research and production of highly accurate and sensitive pathogen detection kits.

Mission

Pharmozyme’s mission is to significantly improve the lives of human beings through the development of novel, effective, and accessible solutions for the biotech community. By providing the highest quality enzymes and customer service, we strive to help genetic research and diagnostic labs thrive.

Leadership

Nader Nourizad, PhD. 
Founder & CEO
A professional entrepreneur with more than 25 years of experiences in the field of protein engineering and assay development in both academia and industry. Nader earned his Ph.D. from Royal Institute of Technology (KTH, Sweden) in Recombinant Enzymes In Pyrosequencing Technology and played a critical role in the development of this novel sequencing technology. He also has conducted years of research at Stanford Genome Technology Center prior to starting Pharmozyme.

Shahriar Rouhani, PhD.
Founder & Chairman
M.A. in Physics from UC Berkeley and a Ph.D. in Theoretical Physics from Yale University. He has more than 33 years of experience serving on the boards of multiple organizations.

Basir Sohail
Executive VP, Global Operations
Formerly VP of Thermo Fischer with more than 20 years of U.S. and international experience in Executive Management and Strategic Business Development. Track record of success in penetrating global markets, introducing novel technologies and driving revenue

Michael Swartzburg, MBA 
Financial Execute Advisor
25 years of global finance, building companies and creating entity value, including over $1 billion of M&A and financing activities 

Yahya Rouhani, MBA
VP, Strategy & Operations
Over 10 years of experience in management, marketing, and international relations

Mark Gebhard, PhD.
Lead Scientist
MS in Chemical Engineering from Stanford and a Chemical Engineering PhD at UT Austin. 5  years of post-graduate experience in both academic and industrial settings

Advisory Board

Dr. Ronald Davis

DIRECTOR, STANDFORD GENOME TECHNOLOGY CENTER

Ali Zareh

MANAGING DIRECTOR AT PARADIGM BIOVENTURES

Gregg Alton

EVP GILEAD MEDICAL AFFAIRS & EMERGING MARKETS

John Stubbs

MANAGING PARTNER OF ROMULUS GLOBAL ISSUES MANAGEMENT

Dr. John Shultz

TECHNOLOGY DIRECTOR, OFFICE OF TECHNOLOGY TRANSFER, HOUSTON METHODIST HOSPITAL

Dr. Peter Griffin

SENIOR SCIENTIST IN THE DEPARTMENT OF ELECTRICAL ENGINEERING AT STANDFORD UNIVERSITY

Dr. Molly He

MANAGING PARTNER OF ROMULUS GLOBAL ISSUES MANAGEMENT